Medtronic will unveil the MiniMed™ 780G system with Simplera Sync™, a new disposable, all-in-one sensor.*

Medtronic plc, the global leader in medical technology, announced the unveiling of new data on its MiniMed™ 780G system at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence on March 6-9, 2024. Medtronic will also provide a first look at the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one sensor requiring no fingersticks or overtape, before its commercial launch in the summer of 2024. New clinical evidence on the MiniMed™ 780G system will focus on three key areas:

• Equalizing Outcomes: Real-world and clinical evidence will be presented to show the MiniMed™ 780G system’s ability to help individuals across diverse populations around the world exceed international consensus goals¹ for time in range (TIR) and glycemic outcomes with the use of recommended settings (100 mg/dL glucose target and active insulin time of 2 hours).
   
• Time in Tight Range (TITR): An analysis of MiniMed™ 780G system data will show that a TITR of >50% is a reasonable goal for users. The advancement of automated insulin delivery (AID) systems has led to the development of a new and emerging TITR metric defined as the percentage of time a person spends in the glucose range of 70-140 mg/dL. TITR lowers the upper threshold of Time in Range from 180 mg/dL to 140 mg/dL, more closely mirroring the glucose levels of individuals without diabetes (referred to as normoglycemia or euglycemia). This supplemental metric provides a goal for individuals with type 1 diabetes desiring even tighter management of glucose levels and less time in hyperglycemia, which can lead to devastating long-term complications.²
   
• Economic Benefits of AID Systems: As decision makers across the world grapple with the long-term costs of diabetes on individuals, healthcare systems and society, Medtronic will also present data that highlights the health economic benefits of automated insulin delivery systems.

SCIENTIFIC DATA

• “A Time in Tight Range (70-140 mg/dL) of >50% is a Reasonable and Safe Treatment Target for Real-World Users of the MiniMed™ 780G System” – e-poster viewing (#423_IUO) by Javier Castañeda, Senior Manager, Statistics, Medtronic Diabetes 
• “The Impact of Meal Bolus Timing on Postprandial Glucose Control with AHCL System: A Prospective Repeated Measure Study” – oral presentation by Maya Laron Hirsh, B.Sc., Sheba Medical Center, Israel on Saturday, March 9, 10:20-10:30 CET (3:20-3:30am CT)
• “The Importance of Recommended Settings and Meal Bolusing with the MiniMed™ 780G System: Real-World Lessons from Puerto Rico” – oral presentation (#1107_IUO) by Matias Castro, Principal Medical Science Liaison Specialist, Medtronic Diabetes, LATAM, on Saturday, March 9, 10:40-10:50 CET (3:40-3:50am CT)
• “Assessment of the Consistency of Clinical Targets for Time in Ranges in Real-Word (RW) Users of the MiniMed™ 780G System” – oral poster (#427_IUO) by Javier Castañeda, Senior Manager, Statistics, Medtronic Diabetes, Netherlands on Saturday, March 9, 11:00-11:30 CET (4:00-4:30am CT)
• “Early Real-World Performance of The MiniMed™ 780G Advanced Hybrid Closed-Loop (AHCL) System and Recommended Settings Use in the United States” – oral presentation (#50_IUO) by James Thrasher, MD, Founder, Arkansas Diabetes and Endocrinology Center, United States on Saturday, March 9, 11:30-11:40 CET (4:30-4:40am CT)
• “Simplified Meal Announcement vs. Precise Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMed™ 780G Advanced Hybrid Closed Loop System: One Year Experience” – e-poster viewing (#222_IUO) by Goran Petrovski, MD, PhD, Endocrinologist and Professor, Sidra Medicine, Qatar
• “Performance Of the MiniMed™ Advanced Hybrid Closed Loop System in Real-World Users with Type 2 Diabetes” – oral presentation (#424_IUO) by Tim van den Heuvel, Principal Medical Affairs Specialist, Medtronic Diabetes, Netherlands on Saturday, March 9, 12:00-12:10 CET (5:00-5:10am CT)
• “A Majority of MiniMed™ 780G System Users Do Not Yet Use Recommended Settings- Time Trend Analyses with Real-World Data” – e-poster viewing (#425_IUO) by Arcelia Arrieta, Principal Clinical IT Developer, Medtronic Diabetes, Netherlands
• “Evaluation of the MiniMed™ 780G System in Young Pediatric Subjects (2-6 Years Old) with Type 1 Diabetes: Design of the Lenny Study” – e-poster viewing (#426_IUO) by Jessica Cellot, Senior Clinical Research Specialist, Medtronic Diabetes, Italy
• “Long-Term Clinical Outcomes of the MiniMed™ 780g Advanced Hybrid Closed-Loop System in India: A Modeling Study” – e-poster viewing (#475_IUO) by Banshi Saboo, MD, Diabetologist and Endocrine Physician, Dia-Care, India
• “Short-Term Economic Benefits in The United Kingdom from the Use of Automated Insulin Delivery Systems in People with Type 1 Diabetes and Raised HbA1C” – e-poster viewing (#598_IUO) by Pratik Choudhary, MD, Professor, Diabetes, University of Leicester, United Kingdom
• “The Health Economics of Automated Insulin Delivery (AID) Systems and the Use of Time in Range (TIR) in Diabetes Health Economics Modeling” – e-poster viewing (#600_IUO) by Chantal Mathieu, MD, PhD, Professor of Medicine, Katholieke Universiteit, Belgium
• “The Effectiveness of the Temp Target Feature in Real-World Users of the MiniMed™ 780G System” – e-poster viewing (#671_IUO) by Vittorino Smaniotto, Senior Medical Affairs and Education Manager, Medtronic Diabetes, Switzerland
• “A Systematic Review: Real-World Evidence of Automated Insulin Delivery (AID) Systems Confirm Pivotal Trial Findings” – e-poster viewing (#764_IUO) by Elizabeth Considine, PhD, Department of Pediatrics, Yale School of Medicine, United States
• “Reducing Diabetes Burden with Automated Insulin Delivery Systems” – e-poster viewing (#771_IUO) by Gregory Forlenza, Associate Professor and Pediatric Endocrinologist, - Barbara Davis Center for Diabetes, University of Colorado School of Medicine, United States 
• “A Recipe for Excellence in the Management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish Cohort” – e-poster viewing (#896_IUO) by Bartłomiej Matejko, PhD, Professor, Jagiellonian University, Poland

MEDTRONIC SPONSORED EVENTS

Medtronic Symposium: Unlocking the full potential of the MiniMed™ 780G system – Navigating complex scenarios and orphan indications in diabetes care. Thursday, March 7, at 10:30-12:00 CET (3:30-5:00am CT), chaired by Prof. Raffaella Buzzetti, MD, Professor of Endocrinology, Sapienza University and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes.

Expert	Topic
Ernesto Maddaloni (Italy) MD, PhD	MiniMed™ 780G's role in addressing Latent Autoimmune Diabetes in Adults in diabetes care
Valeria Grancini (Italy) MD, PhD	MiniMed™ 780G's impact on cystic fibrosis-related diabetes management
Prof. Katrien Benhalima (Belgium) MD, PhD	Enhancing the management of type 1 diabetes care in pregnancy: The role of MiniMed™ 780G system**
Prof. Ohad Cohen (Israel) MD	Navigating orphan indications in diabetes care: Linking it all together

 

MEDTRONIC WORKSHOPS & MINI-SYMPOSIUMS

• Unlocking the full potential of the MiniMed™ 780G system: Navigating complex scenarios and orphan indications in diabetes care Expert Insights,” chaired by Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes with speakers Prof. Katrien Benhalima, Prof. Nick Oliver, Prof. David O’Neal, MD, and Prof. Christophe De Block on, Thursday, March 7, 13:00-14:30 CET (6:00-7:30am CT)
   
• “The smarts behind the Smart MDI system” chaired by Madison Smith, PhD, Senior R&D Clinical Product Manager, Medtronic Diabetes and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes, with speakers, Prof. Peter Adolfsson MD, PhD, and Prof. Bonfanti Riccardo, MD, on Friday, March 8, 9:30-10:30 CET (2:30-3:30am CT)
   
• “Glycemic outcomes and burden of AID systems: Lessons from Pivotal Trials and the Real World from US experts” chaired by Bob Vigersky, MD, Chief Medical Officer, Medtronic Diabetes, with speakers Jennifer McVean, MD, James Thrasher, MD, Jennifer Sherr, MD, and Gregory Forlenza, MD, on Friday, March 8 17:15-18:45 CET (10:15-11:45am CT)

About Medtronic Diabetes (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

*Investigational. Not approved by the FDA for any use and not commercially available in the US.

**The MiniMed™ 780G system has not been approved for use in pregnancy, type 2 diabetes, etc. by FDA or other regulatory bodies; The MiniMed™ 780G system has not been approved for use in pregnancy, type 2 diabetes or cystic fibrotic diabetes.

1. Van den Heuvel T, Arrieta A, Castaneda J, Vigersky R, Cohen O. Consistent performance of the MiniMed™ 780G system across continents: a world-wide real-world analysis. 59th EASD Annual Meeting of the European Association for the Study of Diabetes.

2. “The use of optimal system settings in real-world MiniMed™ 780G system users has a large impact on increasing the time in tight glucose range.” Oral presentation at 59th EASD Annual Meeting of the European Association for the Study of Diabetes by Javier Castañeda, Senior Statistics Manager, Medtronic Diabetes

For more information, contact:
Ashley Patterson
Global Communications
+1 (818) 576-3025

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626